- Home
- XTNT vs NRXP Comparison
XTNT vs NRXP Comparison
Compare XTNT & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XTNT
- NRXP
- Stock Information
- Founded
- XTNT N/A
- NRXP 2015
- Country
- XTNT United States
- NRXP United States
- Employees
- XTNT N/A
- NRXP N/A
- Industry
- XTNT Biotechnology: Biological Products (No Diagnostic Substances)
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- XTNT Health Care
- NRXP Health Care
- Exchange
- XTNT Nasdaq
- NRXP Nasdaq
- Market Cap
- XTNT 60.9M
- NRXP 58.5M
- IPO Year
- XTNT N/A
- NRXP N/A
- Fundamental
- Price
- XTNT $0.63
- NRXP $2.89
- Analyst Decision
- XTNT
- NRXP Strong Buy
- Analyst Count
- XTNT 0
- NRXP 4
- Target Price
- XTNT N/A
- NRXP $28.50
- AVG Volume (30 Days)
- XTNT 69.9K
- NRXP 283.3K
- Earning Date
- XTNT 08-12-2025
- NRXP 08-19-2025
- Dividend Yield
- XTNT N/A
- NRXP N/A
- EPS Growth
- XTNT N/A
- NRXP N/A
- EPS
- XTNT N/A
- NRXP N/A
- Revenue
- XTNT $127,766,000.00
- NRXP N/A
- Revenue This Year
- XTNT $12.68
- NRXP N/A
- Revenue Next Year
- XTNT $5.40
- NRXP $230.95
- P/E Ratio
- XTNT N/A
- NRXP N/A
- Revenue Growth
- XTNT 15.16
- NRXP N/A
- 52 Week Low
- XTNT $0.33
- NRXP $1.10
- 52 Week High
- XTNT $0.78
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- XTNT 51.87
- NRXP 54.48
- Support Level
- XTNT $0.57
- NRXP $2.30
- Resistance Level
- XTNT $0.70
- NRXP $2.68
- Average True Range (ATR)
- XTNT 0.05
- NRXP 0.19
- MACD
- XTNT 0.01
- NRXP 0.02
- Stochastic Oscillator
- XTNT 57.31
- NRXP 89.39
About XTNT Xtant Medical Holdings Inc.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.